Cargando…
Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
The acute toxicity, pharmacokinetics and hypoxic cytotoxicity of RSU-1069 were investigated using the subcutaneous (sc) rat 9L tumour model. The pharmacokinetics were studied after i.p. injection of RSU-1069 (20 mg kg-1 or 100 mg kg-1). For both doses, the elimination of RSU-1069 followed first-orde...
Autores principales: | Wong, K. H., Koch, C. J., Wallen, C. A., Wheeler, K. T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972348/ https://www.ncbi.nlm.nih.gov/pubmed/2021530 |
Ejemplares similares
-
Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).
por: Chaplin, D. J.
Publicado: (1986) -
Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
por: Hill, R. P., et al.
Publicado: (1986) -
Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.
por: Cobb, L. M., et al.
Publicado: (1990) -
The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
por: Stratford, I. J., et al.
Publicado: (1986) -
Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.
por: Adams, G. E., et al.
Publicado: (1984)